Featured Research

from universities, journals, and other organizations

Inherited Cancer Mutation Is Widespread In America

Date:
April 18, 2008
Source:
Ohio State University Medical Center
Summary:
A gene mutation responsible for a form of inherited colon cancer is older than formerly believed. The findings offer a better understanding of the American Founder Mutation, which in North America causes Lynch syndrome, a hereditary cancer syndrome that increases colon-cancer risk. A 2003 study by the same investigators concluded that the mutation arrived in North America in 1727. The new study indicates that the mutation is actually about 500 years old.

A gene mutation responsible for the most common form of inherited colon cancer is older and more common than formerly believed, according to a recent study.

The findings provide a better understanding of the spread and prevalence of the American Founder Mutation, a common cause in North America of Lynch syndrome, a hereditary cancer syndrome that greatly increases a person's risk for developing cancers of the colon, uterus and ovaries.

The same investigators discovered the mutation in 2003. That research identified nine families with the mutation and concluded that a German immigrant couple brought the mutation to North America in 1727.

The latest study includes an additional 32 families and indicates that the mutation is actually about 500 years old, suggesting that it arose several generations earlier in Europeans or perhaps in Native Americans.

Of the 41 families overall, most are clustered in Kentucky, Ohio and Texas.

Scientists at the Ohio State University Comprehensive Cancer Center and Creighton University conducted the study, published recently in the journal Cancer Research.

"The increased age of the American Founder Mutation means that it is significantly more prevalent in the United States than previously thought," says principal investigator Albert de la Chapelle, a researcher with Ohio State's Human Cancer Genetics program.

"Of interest is that this mutation has not been found in Europe, which is tentative evidence, along with hints from family histories, that it may have arisen in a Native American."

The new study estimates that the mutation is present in 32,150 Americans as compared with the earlier figure of 18,981. "But these numbers are theoretical and need to be substantiated by further work," de la Chapelle notes.

"This is an important public health concern," de la Chapelle says, "because individuals with a Lynch syndrome mutation can benefit from earlier and more frequent cancer surveillance."

In addition, he says, a simple, cheap genetic test can detect the mutation.

Lynch syndrome, also known as hereditary nonpolyposis colon cancer, is responsible for about one third of hereditary colon cancers, and almost 3 percent of colon cancer generally, or about 4,500 cases annually in the United States.

The initial study of nine families showed that the American Founder Mutation results in the loss of a very specific piece of a gene called MSH2 (although many other mutations also cause Lynch syndrome).

The new study linked 27 of the 41 families into seven groups through genealogic studies.

The age of the mutation was estimated using certain markers along the DNA located at either end of the mutation. Such patterns of markers are called haplotypes.

When a new person was identified for the study, the DNA on each side of the individual's mutation was tested for the markers, producing a shared haplotype. The shorter the shared haplotype, the older the mutation. This information led to the estimated age of 500 years.

"This data pushed the original founder mutation back to around 1500, plus or minus a number of years," says coauthor Heather Hampel, a genetics counselor and researcher with Ohio State's Human Cancer Genetics Program.

"The Pilgrims began arriving in the 1600s, so the mutation could have arisen first in very early settlers from Europe, or in Native Americans."

"It's unclear whether we'll ever learn who the first person was to have this mutation," Hampel says, "but it is clear that the mutation is much older than we thought and probably more widespread. For that reason, we feel it is potentially a serious public health issue, particularly in states such as Kentucky, Ohio and Texas where it is very prevalent."


Story Source:

The above story is based on materials provided by Ohio State University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University Medical Center. "Inherited Cancer Mutation Is Widespread In America." ScienceDaily. ScienceDaily, 18 April 2008. <www.sciencedaily.com/releases/2008/04/080417155859.htm>.
Ohio State University Medical Center. (2008, April 18). Inherited Cancer Mutation Is Widespread In America. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/04/080417155859.htm
Ohio State University Medical Center. "Inherited Cancer Mutation Is Widespread In America." ScienceDaily. www.sciencedaily.com/releases/2008/04/080417155859.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins